FY2026 EPS Estimates for Zymeworks Boosted by HC Wainwright

Zymeworks Inc. (NASDAQ:ZYME) – Stock analysts at HC Wainwright increased their FY2026 earnings estimates for Zymeworks in a research report issued on Wednesday, August 26th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings per share of $1.51 for the year, up from their previous forecast of $0.31. HC Wainwright has a “Buy” rating and a $55.00 price objective on the stock. The consensus estimate for Zymeworks’ current full-year earnings is $1.25 per share. HC Wainwright also issued estimates for Zymeworks’ Q4 2026 earnings at $0.67 EPS, Q1 2027 earnings at $1.05 EPS, Q2 2027 earnings at ($0.16) EPS, Q3 2027 earnings at $0.76 EPS, Q4 2027 earnings at ($0.34) EPS and FY2027 earnings at $1.32 EPS.

Zymeworks (NASDAQ:ZYME) last issued its quarterly earnings data on Friday, August 7th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.06). The company had revenue of $3.23 million during the quarter, compared to analyst estimates of $4.54 million. Zymeworks had a negative return on equity of 72.30% and a negative net margin of 405.31%.The business’s revenue was down 90.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.03 earnings per share.

Several other research analysts have also commented on ZYME. Deutsche Bank Aktiengesellschaft set a $32.00 price target on Zymeworks in a research report on Wednesday. Truist Financial increased their target price on Zymeworks from $31.00 to $32.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Wells Fargo & Company raised their target price on Zymeworks from $37.00 to $40.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Stifel Nicolaus set a $46.00 target price on Zymeworks in a research report on Friday, August 7th. Finally, Citigroup reiterated a “market outperform” rating on shares of Zymeworks in a research note on Wednesday. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Zymeworks has an average rating of “Moderate Buy” and a consensus target price of $40.00.

Zymeworks Stock Down 1.0%

Shares of NASDAQ ZYME opened at $29.01 on Friday. The firm has a market cap of $2.06 billion, a price-to-earnings ratio of -14.36 and a beta of 1.15. Zymeworks has a 52-week low of $13.60 and a 52-week high of $30.62. The business’s 50 day moving average is $24.84 and its two-hundred day moving average is $24.81.

Institutional Trading of Zymeworks

Several hedge funds have recently modified their holdings of ZYME. Nykredit A S purchased a new position in Zymeworks in the second quarter valued at $25,000. Caitong International Asset Management Co. Ltd purchased a new stake in Zymeworks during the 4th quarter worth about $37,000. Quarry LP purchased a new stake in Zymeworks during the 3rd quarter worth about $50,000. Tower Research Capital LLC TRC raised its position in Zymeworks by 29.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,947 shares of the company’s stock valued at $62,000 after purchasing an additional 1,131 shares in the last quarter. Finally, State of Wyoming acquired a new stake in Zymeworks in the 2nd quarter valued at about $73,000. 92.89% of the stock is currently owned by institutional investors and hedge funds.

Zymeworks declared that its Board of Directors has initiated a stock repurchase plan on Thursday, May 14th that authorizes the company to repurchase $125.00 million in shares. This repurchase authorization authorizes the company to buy up to 7% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board believes its stock is undervalued.

More Zymeworks News

Here are the key news stories impacting Zymeworks this week:

• Positive Sentiment: FDA approval expands the commercial opportunity for Ziihera. Jazz Pharmaceuticals received FDA approval to use Ziihera (zanidatamab) as a first-line treatment for HER2-positive, locally advanced unresectable or metastatic gastroesophageal adenocarcinoma. Because Zymeworks developed and partnered the therapy, the expanded indication could increase future royalties, milestone payments and the drug’s overall market opportunity. Jazz Secures FDA Nod for Expanded Use of Ziihera in Gastric Cancer
• Positive Sentiment: Analysts raised their valuation expectations. HC Wainwright increased its ZYME price target from $51 to $55 while maintaining a Buy rating. Citigroup also raised its target from $37 to $38 and retained a Buy rating, while Citizens JMP reaffirmed its Market Outperform rating with a $32 target. These targets indicate that analysts continue to see substantial upside based on Zymeworks’ oncology pipeline and Ziihera-related potential. Analyst Price Target Updates
• Positive Sentiment: HC Wainwright modestly increased its Q3 2026 earnings forecast to $2.14 per share from $2.13 and maintained its Buy rating and $55 price target. While the estimate change was small, it reinforces the firm’s constructive view of Zymeworks’ earnings outlook.
• Neutral Sentiment: Investor attention has increased following the FDA decision. ZYME was among healthcare stocks highlighted after the gastroesophageal cancer approval, helping explain its move toward a 52-week high. The news improves visibility but does not by itself guarantee near-term revenue or royalty results. SJM, ZYME Stocks Hit 52-Week High
• Negative Sentiment: Recent financial results remain a counterweight. Zymeworks’ latest quarter missed analysts’ EPS and revenue estimates, with revenue down sharply year over year and the company continuing to report losses. Investors may therefore remain focused on the pace at which Ziihera’s expanded approval translates into royalties and sustainable earnings.

Zymeworks Company Profile

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.